Biotron appoints advisor for China strategy

Latest News

Biotron (ASX:BIT) has announced the appointment of Shanghai based advisory group, Lynx Financial, as corporate advisor to assist with the execution of its China commercialisation strategy.

According to the company, Lynx Financial will assist in identifying and negotiating with suitable partners to enable the licensing of its antiviral drug platform to the People’s Republic of China.  

Biotron’s managing director, Dr Michelle Miller, said, “The Company believes there is a significant opportunity to execute a regional licensing agreement for its antiviral drug platform in China. Respiratory and emerging viruses are an issue in China as in the rest of the world, and Hepatitis C virus (HCV) remains a significant problem in the region.”

Managing director of Lynx Financial, Mr Donald Xu, said, “we are very excited to be working with Biotron; China is now the second largest pharmaceutical market in the world and growing at a significant rate. We believe Biotron’s antiviral platform represents a strong regional partnering opportunity here in China and we look forward to assisting the company in executing its China strategy.”

Biotron has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs. The company’s focus is designing drugs that target a class of virus protein known as viroporins that have a role in the virus life cycle of a very broad range of viruses.